Enquirer Consulting Group

Reachable Buyer Map

Prepared for Generoso Ianniciello · Anima Biotech · August 2026
Anima's public track record runs on collaborations with drug companies rather than on a product with a list price. In that model the reachable market reads differently: small enough to name in full, and hard to reach because the deciding seat is different inside every organization. This map covers the United States: those seats, the segments they sit in, and roughly how many of each there are. It describes the market rather than your business, and there is nothing to buy at the end of it.
Large research-based pharma
The smallest count on this page and the largest commitments. Each company is really several buying centers at once: a target discovery group, a modality group and a corporate development team that rarely hold the same view of the same platform.
Who signs: head of external innovation, search and evaluation lead, VP of discovery biology, therapeutic area head, and the chief scientific officer on platform deals.
Roughly 25 to 35
global research-based pharmaceutical companies running full discovery organizations, most with several US research sites and a separate decision seat in each
Mid-cap and commercial-stage biopharma
Large enough to fund external science and small enough that one scientific champion can carry it internally. The segment where a platform conversation most often becomes a real collaboration inside a single fiscal year.
Who signs: chief scientific officer, VP of research, head of business development, head of translational sciences.
250 to 350
US biopharmaceutical companies with products on the market or in late-stage development
Clinical-stage biotech
Moves quickly, decides in one room, and is where platform validation and publications usually come from. Also the shortest attention span of any segment here, because the pipeline in front of them is the only thing being funded.
Who signs: chief scientific officer, founder or CEO, VP of biology, head of platform or technology.
2,800 to 3,400
US employers registered in biotechnology and pharmaceutical research and development
Discovery services and contract research
Not an end customer so much as a channel. They sit inside dozens of discovery programs at once and they get asked what to use, which makes a single relationship here worth several direct ones.
Who signs: head of scientific partnerships, chief scientific officer, VP of business development, scientific director.
700 to 900
US contract research and discovery services employers
Foundations and disease research funders
They fund the targets nobody else will, they introduce their portfolios, and they almost never get approached commercially. Long-dated, low-volume, and disproportionately useful for a platform that needs biology nobody has resolved yet.
Who signs: chief scientific officer, director of research programs, venture philanthropy lead, scientific advisory chair.
400 to 600
US medical research foundations and disease-specific funding organizations
Academic and hospital translational centers
Cheap to start and slow to convert, and the one segment where a named principal investigator matters more than the institution. Worth mapping because the same names reappear on the advisory boards of every segment above.
Who signs: director of technology transfer, center or institute director, principal investigator, associate dean for research.
150 to 200
US academic medical centers and research institutes with an active technology transfer office

Where the openings are

1
The market is small enough to name, and that changes the method. Add the segments above and it lands between four and six thousand organizations, holding a countable number of seats that can actually start a collaboration. That is not a volume problem. It is a coverage problem: reaching all of them by name, more than once, and knowing exactly who answered.
2
A platform gets judged by whoever opens the message first. Discovery biology reads it as a tool, external innovation reads it as a deal, and business development reads it as a term sheet. One message cannot satisfy all three, and no large company forwards it internally on your behalf. Three audiences, three approaches, one piece of science.
3
The people move, and every move reopens a closed conversation. Therapeutic area heads and external innovation leads change roles constantly, and the new one revisits everything the last one declined. Watching a few thousand named seats for that change is mechanical work that nobody does by hand, and it is the most reliable opening in this market.
4
Partnering conferences reach the companies that traveled. They are a strong channel and a narrow one: they reach whoever already sent someone with a slot to fill. The organizations most worth a first conversation are usually the ones that did not come.
Built from public registries covering US employers and published facility listings, current to the most recent filing year. Counts are banded deliberately. Sites are not companies: a group can run many locations and file once, so the segments overlap at the edges. Owner-only and very small operators are not published in this data, and sector codes are self-reported.
ENQUIRER CONSULTING GROUP
enquirerconsulting.com